arGEN-X signs development agreement with Lilly


Will receive licence fees and research funding

Dutch biopharmaceutical firm arGEN-X has entered into an alliance with Eli Lilly and Company for the discovery and development of novel therapeutic antibody products against targets submitted by Lilly.

arGEN-X will generate novel human monoclonal antibody (mAb) candidates that act on various functional sites on Lilly targets.

Lilly will have the option to select the most promising mAb candidates to take forward into preclinical and clinical development and potential commercialisation.

Under the terms of the agreement, arGEN-X will receive licence fees and research funding, as well as potential milestone payments.

Other financial and deal terms were not disclosed.

arGEN-X focuses on the discovery and development of human antibodies using its proprietary SIMPLE Antibody platform.

Tim Van Hauwermeiren, chief executive of arGEN-X, said: ‘The signing of this alliance with Lilly is a major highlight for arGEN-X and is evidence of the potential of our SIMPLE Antibody platform.’